Publications by authors named "Gene P L Ambrocio"
Article Synopsis
- Chronic lung allograft dysfunction (CLAD) has three main types: bronchiolitis obliterans syndrome (BOS), restrictive allograft syndrome (RAS), and a mixed type combining both.
- A study looked at how the structure of airways changes in these types and found that BOS and mixed cases had more blockage in the larger airways compared to RAS, which had problems lower down in the smaller airways.
- These blockages were mostly caused by inflammation and scarring, leading to problems with breathing in all CLAD types.
Pulmonary alveolar proteinosis (PAP) is a rare, diffuse lung disorder characterized by surfactant accumulation in the small airways due to defective clearance by alveolar macrophages, resulting in impaired gas exchange. Whole lung lavage is the current standard of care treatment for PAP. Lung transplantation is an accepted treatment option when whole lung lavage or other experimental treatment options are ineffective, or in case of extensive pulmonary fibrosis secondary to PAP.
View Article and Find Full Text PDFIn recent years, the utility of vascular complement factor 4d (C4d) deposition as diagnostic tool for antibody mediated rejection (AMR) after lung transplantation, has become a controversial issue. We aimed to pinpoint the problematic nature of C4d as biomarker with a simple experiment. We quantified C4d in broncho-alveolar lavage (BAL) of lung transplant patients with diverse post-transplant complications in 3 different settings of clinically clear cases of: 1/ chronic lung allograft dysfunction (CLAD); 2/ acute complications acute rejection (AR), lymphocytic bronchiolitis (LB), antibody-mediated rejection (AMR) and respiratory infection (INF); 3/ patients with parallel C4d immunostaining and Anti-HLA.
View Article and Find Full Text PDFLimited results about treatment with total lymphoid irradiation (TLI) in lung transplant (LTx) recipients suffering from progressive bronchiolitis obliterans syndrome (BOS) have been reported. We performed a retrospective analysis of all LTx recipients undergoing TLI for progressive BOS in our center, focusing on long-term outcomes regarding overall survival and lung allograft function. Treatment with TLI (2004-2017, n = 20, 1 BOS stage 1, 6 BOS stage 2, and 13 BOS stage 3) resulted in significant attenuation of the FEV -decline in the majority of patients, mainly in those with a rapid decline (P = 0.
View Article and Find Full Text PDF